Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 919-925

  Bradbury, Brian D ^a   Critchlow, Cathy W ^a   Weir, Matthew R ^b   Stewart, Ron ^a   Krishnan, Mahesh ^a   Hakim, Raymond H ^c  

^a AMGEN INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Anemia; C reactive protein; End stage renal disease; Epoetin alfa; Erythropoiesis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR ACCESS;

ADULT; AGED; C-REACTIVE PROTEIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 60749137146     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn543     Document Type: Article

References (32)

1. Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif 2002; 20: 70-80
2. den Elzen WP, van Manen JG, Boeschoten EW et al. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006; 21: 1588-1595
3. Honda H, Qureshi AR, Heimburger O et al. Serumalbumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, andmortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
4. Menon V, Wang X, Greene T et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44-52
5. Racki S, Zaputovic L, Mavric Z et al. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail 2006; 28: 427-433
6. Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798
7. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17(Suppl 8): 29-32; (discussion) 39-40
8. Yeun JY, Levine RA, Mantadilok V et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
9. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
10. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
11. Stigant CE, Djurdjev O, Levin A. C-reactive protein levels in patients on maintenance hemodialysis: reliability and reflection on the utility of single measurements. Int Urol Nephrol 2005; 37: 133-140
12. Boenisch O, Ehmke KD, Heddergott A et al. C-reactive-protein and cytokine plasma levels in hemodialysis patients. J Nephrol 2002; 15: 547-551
13. Kaysen GA, Levin NW, Mitch WE et al. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients. Blood Purif 2006; 24: 508-516
14. van Tellingen A, Grooteman MP, Schoorl M et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002; 62: 632-638
15. Beerenhout CH, Kooman JP, Van Der Sande FM et al. C-reactive protein levels in dialysis patients are highly variable and strongly related to co-morbidity. Nephrol Dial Transplant 2003; 18: 221
16. USRDS. USRDS 2006 Annual Data Report: US Renal Data System. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
17. Roberts TL, Obrador GT, St Peter WL et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66: 2429-2436
18. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800
19. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
20. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000
21. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
22. Bradbury BD, Critchlow CW, Rothman KJ et al. Exploring relative mortality and Epoetin alfa among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70
23. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
24. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
25. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21:991-998
26. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
27. Kausz AT, Solid C, Pereira BJ et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?. Am J Kidney Dis 2005; 45: 136-147
28. Papayannopoulou T, D'Andrea A, Abkowitz A et al. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R, Benz E, Shattil SJ et al. (eds). Hematology: Basic Principles and Practice, 4th edn. Philadelphia, PA: Elsevier Churchill Livingstone, 2005
29. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003; 31: S651-S657
30. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
31. Malyszko J, Malyszko JS, Hryszko T et al. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol 2005; 25: 586-590
32. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093